Peer-reviewed veterinary case report
Brain metastases from solid cancers in 58 dogs
By Okonji, Samuel et al.·Published in Veterinary medicine and science·2025·Department of Veterinary Medical Sciences, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Brain Metastases From Solid Cancers in 58 Dogs.
- Species:
- dog
Plain-English summary
A study looked at 58 dogs with brain metastases (cancer spread to the brain) from solid tumors like haemangiosarcoma and carcinoma. Most of these dogs showed neurological symptoms, and the average survival time after diagnosis was just 3 days, with very few living beyond a few months. Treatment options were limited and did not improve outcomes. Unfortunately, the prognosis for dogs with brain metastases is generally poor, especially for those with certain types of cancer or existing metastases at the time of diagnosis.
People also search for: dog brain cancer symptoms · haemangiosarcoma prognosis in dogs · treatment for dog brain metastases
Abstract
Brain metastases (BM) represent an unmet medical need in human medicine, and they are poorly documented in dogs. The aim of this multi-centre retrospective study was to report the clinical characteristics, primary solid cancer histology, advanced imaging findings, treatment modalities and potential prognostic factors in dogs with presumed BM that occurred either at the time of initial diagnosis or during follow-up. BM diagnosis was established through either imaging studies or histologic examination of specimens obtained during necropsy. A total of 58 client-owned dogs with histologically proven solid cancer and BM were included. Clinicopathologic variables, BM characteristics based on imaging and survival post-BM (SPBM) were recorded. Haemangiosarcoma (53.4%) and carcinoma (27.6%) were the most common primary tumour histotypes, followed by melanoma (12.1%) and undifferentiated sarcoma (6.9%). Synchronous BM and solitary BM occurred in 63.8% and 51.7% of dogs, respectively. The prosencephalus was most commonly affected, with 79% of dogs showing neurologic deficits. Antitumoural or palliative treatment was attempted in a minority of dogs, with no improved outcome. The median SPBM was 3 days (range, 1-255). The 3- and 6-month survival rates were 8.6% and 1.7%, respectively. Dogs with haemangiosarcoma (OR: 7.6; 95% CI, 2.2-25.8; p = 0.001) and those with distant metastases at presentation (OR: 16; 95% CI, 4.2-60.9; p < 0.001) had an increased likelihood of developing synchronous BM. Haemangiosarcoma and carcinoma were the tumours most frequently associated with BM, which were more commonly synchronous and symptomatic, with a high incidence of forebrain localization. The prognosis was poor, regardless of the primary cancer type.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40454864/